
FDA Rationale for Recognition Decision: Amoxicillin and Clavulanate against Haemophilus influenzae
FDA has reevaluated data supporting amoxicillin/clavulanate breakpoints against Haemophilus influenzae. The review included a publication describing the Clinical and Laboratory Standards Institute (CLSI) rationale for revision of the amoxicillin/ …